Skeletal Biotech Laboratory, Faculty of Dental Medicine, Hebrew University, Hadassah Medical Campus, POB 12272, Ein Kerem, Jerusalem, 91120, Israel.
Curr Osteoporos Rep. 2014 Mar;12(1):41-7. doi: 10.1007/s11914-013-0184-x.
Osteoporosis is a debilitating disease that affects millions of people worldwide. Current osteoporosis treatments are predominantly bone-resorbing drugs that are associated with several side effects. The use of stem cells for tissue regeneration has raised great hope in various fields of medicine, including musculoskeletal disorders. Stem cell therapy for osteoporosis could potentially reduce the susceptibility of fractures and augment lost mineral density by either increasing the numbers or restoring the function of resident stem cells that can proliferate and differentiate into bone-forming cells. Such osteoporosis therapies can be carried out by exogenous introduction of mesenchymal stem cells (MSCs), typically procured from bone marrow, adipose, and umbilical cord blood tissues or through treatments with drugs or small molecules that recruit endogenous stem cells to osteoporotic sites. The main hurdle with cell-based osteoporosis therapy is the uncertainty of stem cell fate and biodistribution following cell transplantation. Therefore, future advancements will focus on long-term engraftment and differentiation of stem cells at desired bone sites for tangible clinical outcome.
骨质疏松症是一种影响全球数百万人的衰弱性疾病。目前的骨质疏松症治疗方法主要是骨吸收药物,这些药物与多种副作用有关。干细胞在组织再生方面的应用在包括肌肉骨骼疾病在内的许多医学领域带来了巨大的希望。骨质疏松症的干细胞疗法可以通过增加数量或恢复能够增殖并分化为成骨细胞的驻留干细胞的功能,从而降低骨折的易感性并增加丢失的矿物质密度。这种骨质疏松症的治疗方法可以通过外源性引入间充质干细胞(MSCs)来进行,这些细胞通常从骨髓、脂肪和脐带血组织中获得,或者通过使用招募内源性干细胞到骨质疏松部位的药物或小分子进行治疗。基于细胞的骨质疏松症治疗的主要障碍是细胞移植后干细胞命运和生物分布的不确定性。因此,未来的进展将集中在期望的骨部位的干细胞的长期植入和分化上,以实现切实的临床效果。